Dorothée Sémiond

1.7k total citations
42 papers, 1.2k citations indexed

About

Dorothée Sémiond is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Dorothée Sémiond has authored 42 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 22 papers in Hematology and 21 papers in Molecular Biology. Recurrent topics in Dorothée Sémiond's work include Multiple Myeloma Research and Treatments (22 papers), Cancer Treatment and Pharmacology (15 papers) and Protein Degradation and Inhibitors (9 papers). Dorothée Sémiond is often cited by papers focused on Multiple Myeloma Research and Treatments (22 papers), Cancer Treatment and Pharmacology (15 papers) and Protein Degradation and Inhibitors (9 papers). Dorothée Sémiond collaborates with scholars based in France, United States and Spain. Dorothée Sémiond's co-authors include Patricia Vrignaud, Hervé Bouchard, Marie-Christine Bissery, M Besenval, Alain C. Mita, Eric K. Rowinsky, Leonel Ochoa, Bahram Forouzesh, Amita Patnaik and Andrew Goetz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Dorothée Sémiond

41 papers receiving 1.2k citations

Peers

Dorothée Sémiond
Prabhjot Kaur United States
Susan Ashton United Kingdom
Todd R. Palmby United States
Lance Leopold United States
Chengying Xie China
Gisele Sarosy United States
Jeffrey Yachnin Sweden
Silvia La Monica Italy
Charlotte Kopitz Germany
D. Frye United States
Prabhjot Kaur United States
Dorothée Sémiond
Citations per year, relative to Dorothée Sémiond Dorothée Sémiond (= 1×) peers Prabhjot Kaur

Countries citing papers authored by Dorothée Sémiond

Since Specialization
Citations

This map shows the geographic impact of Dorothée Sémiond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dorothée Sémiond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dorothée Sémiond more than expected).

Fields of papers citing papers by Dorothée Sémiond

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dorothée Sémiond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dorothée Sémiond. The network helps show where Dorothée Sémiond may publish in the future.

Co-authorship network of co-authors of Dorothée Sémiond

This figure shows the co-authorship network connecting the top 25 collaborators of Dorothée Sémiond. A scholar is included among the top collaborators of Dorothée Sémiond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dorothée Sémiond. Dorothée Sémiond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Quach, Hang, Gurdeep Parmar, Enrique M. Ocio, et al.. (2024). A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica. 109(12). 4078–4082. 2 indexed citations
2.
Sémiond, Dorothée, et al.. (2024). Isatuximab–dexamethasone–pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/II data. CPT Pharmacometrics & Systems Pharmacology. 13(12). 2087–2101. 1 indexed citations
3.
Sun, Mingyuan, Hongmei Jing, Fei Dong, et al.. (2024). Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma. Scientific Reports. 14(1). 27550–27550.
4.
Vincenti, Flavio, Oriol Bestard, Josep M. Cruzado, et al.. (2023). Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant. Journal of the American Society of Nephrology. 35(3). 347–360. 14 indexed citations
5.
Shitara, Yoshihisa, et al.. (2023). Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients. CPT Pharmacometrics & Systems Pharmacology. 12(12). 1846–1858. 2 indexed citations
6.
7.
8.
9.
Durán, George E., Volker Derdau, Dietmar Weitz, et al.. (2018). Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein. Cancer Chemotherapy and Pharmacology. 81(6). 1095–1103. 35 indexed citations
10.
Maison‐Blanche, Pierre, Shaker R. Dakhil, Ari David Baron, et al.. (2014). An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 73(6). 1241–1252. 1 indexed citations
11.
Vrignaud, Patricia, et al.. (2014). Preclinical profile of cabazitaxel. Drug Design Development and Therapy. 8. 1851–1851. 66 indexed citations
12.
Vrignaud, Patricia, Dorothée Sémiond, Pascale Lejeune, et al.. (2013). Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors. Clinical Cancer Research. 19(11). 2973–2983. 191 indexed citations
13.
Sémiond, Dorothée, Sukhvinder Sidhu, Marie-Christine Bissery, & Patricia Vrignaud. (2013). Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel. Cancer Chemotherapy and Pharmacology. 72(3). 515–528. 28 indexed citations
14.
Dièras, Véronique, Alain Lortholary, Valérie Laurence, et al.. (2012). Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study. European Journal of Cancer. 49(1). 25–34. 47 indexed citations
15.
16.
Dumez, Herlinde, Ahmad Awada, Martine Piccart, et al.. (2006). A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. Annals of Oncology. 17(7). 1158–1165. 15 indexed citations
17.
Rea, D., J. W. R. Nortier, W.W. ten Bokkel Huinink, et al.. (2005). A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Annals of Oncology. 16(7). 1123–1132. 69 indexed citations
18.
Cisternino, Salvatore, et al.. (2003). Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats. British Journal of Pharmacology. 138(7). 1367–1375. 93 indexed citations
19.
Sessa, Cristiana, C. Cuvier, S. Caldiera, et al.. (2002). Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Annals of Oncology. 13(7). 1140–1150. 37 indexed citations
20.
Kirkesseli, Stéphane, et al.. (1998). A bridging study of fananserin in schizophrenic patients.. PubMed. 34(4). 811–8. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Prabhjot Kaur Breakdown of academic impact, for papers by Susan Ashton Breakdown of academic impact, for papers by Todd R. Palmby Breakdown of academic impact, for papers by Lance Leopold Breakdown of academic impact, for papers by Chengying Xie Breakdown of academic impact, for papers by Gisele Sarosy Breakdown of academic impact, for papers by Jeffrey Yachnin Breakdown of academic impact, for papers by Silvia La Monica Breakdown of academic impact, for papers by Charlotte Kopitz Breakdown of academic impact, for papers by D. Frye
Rankless by CCL
2026